Core Insights - Cencora reported revenue of $80.66 billion for the quarter ended June 2025, reflecting an 8.7% increase year-over-year and surpassing the Zacks Consensus Estimate of $80.33 billion by 0.41% [1] - The company's EPS for the quarter was $4.00, up from $3.34 in the same quarter last year, exceeding the consensus EPS estimate of $3.78 by 5.82% [1] Revenue Breakdown - Total U.S. Healthcare Solutions revenue was $72.88 billion, slightly above the average estimate of $72.81 billion, marking an 8.5% year-over-year increase [4] - Total International Healthcare Solutions revenue reached $7.79 billion, exceeding the average estimate of $7.3 billion, with a year-over-year growth of 10.5% [4] - Intersegment eliminations reported at $-3.47 million, better than the estimated $-3.89 million, showing a significant year-over-year change of 63.6% [4] Stock Performance - Cencora's shares have returned -1.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]